The Ever-Changing Options for the Treatment of CLL

Faculty

Kerry A. Rogers, MD
Associate Professor
Department of Internal Medicine, Division of Hematology
The Ohio State University
Columbus, OH
Matthew S. Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Beth  Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland, OH

Statement of Need

The treatment landscape for CLL has changed dramatically in the past 10 years. With three approved BTK inhibitors, and several more on the horizon, choosing which agent to use in the first-line continues to present a challenge to hematologists/oncologists and care teams. As the choice of first-line agent has ramifications for future lines of therapy, hematologists/oncologists need to be able to map out the treatment journey while keeping in mind that therapy resistance or intolerance may arise and that AEs may diminish adherence to therapy.

In this Creative Educational Concepts Enduring Webcast, expert faculty will guide learners through the latest clinical data that informs best practices (including sequencing BTKis), the rationale and support for combination therapies, and the need to factor in the needs and preferences of patients.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Evaluate emerging efficacy and safety clinical trial data for the treatment of CLL relative to existing data
  • Utilize updated guidelines and evidence supporting the use of combination regimens for the treatment of CLL
  • Develop treatment plans for patients with CLL across multiple lines of therapy while supporting the needs and preferences of patients

Financial Support

Supported through independent educational grants from AstraZeneca Pharmaceuticals and Lilly.

Target Audience

Hematologist oncologists and allied oncology health care practitioners (HCPs) including oncology pharmacists, nurses, nurse practitioners (NPs), and physician associates (PAs)

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center with ILNA

This activity is designated for 1.50 contact hours.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Oncology Nursing Practice (Scientific Basis/Profession), Treatment Modalities, Diagnosis, Staging & Treatment Planning, Cancer Treatment, Side Effect & Symptom Management, Coordination of Care, Diagnosis, Staging & Treatment Planning, Cancer Treatm

Accreditation Council for Pharmacy Education

This Application-based activity is approved for 1.50 contact hours ( 0.15 CEUs) of continuing pharmacy credit ( JA0007101-0000-23-015-H01-P ).

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Rogers reports the following financial relationships:

Advisory Board: AbbVie Inc.; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LOXO@Lilly; and Pharmacyclics LLC
Consultant: AbbVie Inc. and Pharmacyclics LLC
Research Support: AbbVie Inc.; Genentech, Inc.; and Novartis (paid to institution)

Dr. Davids reports the following financial relationships:

Consultant: AbbVie Inc.; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Meyer Squibb Company; Lilly; Genentech, Inc.; GENMA Pharma; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Nuvalent; Secura Bio, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and TG Therapetics, Inc.
Grants: Ascentage Pharma; MEI Pharma, Inc.; and Novartis Pharmaceuticals Corporation
Other financial or material support: UpToDate – authorship royalties

Dr. Faiman reports the following financial relationships:

Consultant: Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc; Karyopharm; Pfizer Inc.; and Sanofi

 

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Nichole Lainhart (Planning Committee)
Keshia Pitt, PhD (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com

WCV-080-122223-90

Call us at 859-260-1717  •  info@ceconcepts.com

The Ever-Changing Options for the Treatment of CLL
Activity Date: 12/22/2023